Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2A Randomized, Double-blinded, Placebo-controlled, Multicenter, Dose Ranging Study of Safety and Efficacy of ATI-2173 in Combination With Tenofovir Disoproxil Fumarate in Subjects With Chronic Hepatitis B Virus Infection and in Subjects With Hepatitis D Virus Coinfection

Next Previous
Trial Profile

A Phase 2A Randomized, Double-blinded, Placebo-controlled, Multicenter, Dose Ranging Study of Safety and Efficacy of ATI-2173 in Combination With Tenofovir Disoproxil Fumarate in Subjects With Chronic Hepatitis B Virus Infection and in Subjects With Hepatitis D Virus Coinfection

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 21 Nov 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ATI-2173 (Primary) ; Imdusiran (Primary) ; Tenofovir disoproxil fumarate
  • Indications Hepatitis B; Hepatitis D
  • Focus Adverse reactions; Pharmacodynamics; Proof of concept
  • Acronyms SAVE 1
  • Sponsors Antios Therapeutics

Most Recent Events

  • 15 Nov 2022 Status changed from active, no longer recruiting to discontinued.
  • 26 Jun 2022 Results assessing antiviral efficacy of ATI-2173 combined with tenofovir disoproxil fumarate in chronic hepatitis B patients, presented at The International Liver Congress 2022.
  • 25 Jun 2022 According to an Antios Therapeutics media release, data from this study were presented at the European Association for the Study of the Liver's International Liver Congress 2022 (EASL ILC 2022).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top